Oxis Turbohaler 6 (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate, the active ingredient in Oxis Turbohaler 6, is a long‑acting β2‑adrenergic agonist presented as a dry‑powder inhaler for inhalation use. It provides bronchodilation for patients with reversible airway obstruction. GNH USA supplies Oxis Turbohaler 6 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oxis Turbohaler 6 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Formoterol fumarate dihydrate is a bronchodilator that acts on the airway smooth‑muscle pathway to improve airflow in chronic respiratory disease.

- Asthma: improves symptom control and reduces the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): enhances bronchodilation and supports maintenance therapy. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Formoterol may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Tremor: mild, transient shaking of the hands or limbs. - Headache: dull or throbbing discomfort, often resolving without intervention. - Throat irritation: mild soreness or dryness after inhalation. - Cough: brief episodes triggered by the inhaled powder. - Palpitations: sensation of rapid or irregular heartbeat, usually transient. - Nasal congestion: mild blockage or runny nose.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of airway obstruction requiring immediate medical attention. - Cardiac arrhythmias: irregular heart rhythms that may be life‑threatening. - Hypokalemia: low blood potassium levels that can affect muscle function. - Severe allergic reaction: rash, swelling, or difficulty breathing indicating anaphylaxis.

When using Formoterol, patients and clinicians should observe several safety measures.

- Assess baseline lung function: perform spirometry before initiating therapy. - Monitor for cardiovascular effects: watch for tachycardia, palpitations, or hypertension. - Avoid abrupt discontinuation: taper under medical supervision to prevent rebound bronchoconstriction. - Use with a rescue inhaler: maintain a short‑acting bronchodilator for acute symptoms. - Educate on inhaler technique: ensure correct use to maximize drug delivery and minimize oral deposition. - Store at ambient temperature: keep below 25°C, in the original packaging, protected from moisture and direct sunlight.

Formoterol can interact with several drug classes, altering its safety profile or efficacy.

Major Interactions (Avoid): - Non‑selective β‑blockers: may diminish bronchodilator response and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): increase the risk of cardiovascular side effects. - Diuretics (especially loop diuretics): may exacerbate hypokalemia when combined with Formoterol.

Moderate Interactions (Monitor Closely): - Other β2‑agonists: additive bronchodilator effect can raise the risk of tachycardia. - Theophylline: may increase plasma concentrations of Formoterol. - Anticholinergics: combined use may enhance bronchodilation but requires monitoring for dry mouth and urinary retention.